Myositis Treatment Options Explained: Medicines, Therapy and Long-Term Care

Living with myositis can be confusing, especially when the treatment plan seems to involve several medicines, regular tests and different specialists. There is no single treatment that works for every person with myositis. Treatment depends on the type of myositis, the muscles and organs affected, how active the disease is and how the patient responds to treatment. For many autoimmune inflammatory myopathies, treatment aims to control disease activity, limit muscle and organ damage, preserve function and improve quality of life. Treatment goals differ in inclusion body myositis, where rehabilitation and supportive care remain particularly important.

What is the first step in myositis treatment?

For many patients, corticosteroids are used at the beginning of treatment because they can reduce active inflammation relatively quickly. Prednisolone is commonly used, while intravenous methylprednisolone may be considered in severe situations. The dose is then adjusted according to the patient's response. Steroids should never be stopped suddenly or reduced without medical supervision because the body needs time to adjust as the dose is lowered. 

Although steroids can be very effective, long-term use can cause problems such as weight gain, diabetes, osteoporosis, cataracts, mood changes and increased susceptibility to infections. This is why doctors often introduce other medicines that can control the disease while allowing the steroid dose to be reduced.

Immunosuppressive medicines and steroid-sparing treatment

Medicines such as methotrexate, azathioprine and mycophenolate mofetil may be used as part of longer-term treatment. Tacrolimus and ciclosporin can also have a role in selected patients, particularly when particular organ involvement or disease characteristics make them appropriate. The choice is not simply based on the diagnosis of myositis. Doctors also consider lung involvement, skin disease, antibody profile, other medical conditions and potential side effects. 

This is particularly important because inflammatory myopathies are a group of different diseases rather than one uniform condition. A medicine that is suitable for one patient may not be the right choice for another.

When are IVIG and biologic treatments considered?

IVIG may be used in selected patients with active myositis, including severe or treatment-resistant disease and particular manifestations such as significant dysphagia. It also has established clinical-trial evidence in adult dermatomyositis. IVIG has an established role in selected patients with active or difficult-to-treat myositis, including some cases of dermatomyositis and swallowing difficulties. Rituximab may be considered in refractory disease, particularly in certain antibody-positive patients. 

These treatments are specialist decisions. IVIG can also be expensive, which can make access difficult for some patients in India. 

Physiotherapy is part of treatment too

Medicine is only one part of myositis care. Once inflammation is being appropriately managed, supervised physical activity and rehabilitation can help preserve muscle strength, mobility and independence. Current guidance supports exercise and rehabilitation as part of myositis management rather than prolonged inactivity. 

The type and intensity of exercise need to be personalised. Someone with active, severe disease may need a very different programme from someone whose disease is stable. Physiotherapists can also help patients adapt everyday movements and conserve energy.

Patients with swallowing problems may need assessment and support from speech and swallowing specialists. Those with lung involvement may require respiratory evaluation and treatment. Skin symptoms, joint problems, nutritional difficulties, fatigue and emotional wellbeing may also need attention.

Long-term care means regular monitoring

Myositis treatment does not end when symptoms improve. Regular follow-up helps doctors assess muscle strength, disease activity, blood tests and treatment side effects. Depending on the patient's symptoms, monitoring may also include lung, heart or swallowing assessments.

For patients in India, it can help to keep a record of medicines, previous test reports, hospitalisations and changes in symptoms. Myositis can change over time, so communication between the patient and treating team matters.

There is also no universal timetable for recovery. Some patients respond relatively quickly, while others need several changes in treatment before disease control is achieved. Inclusion body myositis, in particular, behaves differently from many other inflammatory myopathies and currently has limited effective disease-modifying treatment options. 

How Myositis India can support patients

Finding appropriate information and specialist care can be difficult when a disease is rare. Myositis India works as a non-profit patient support and advocacy organisation, connecting patients and caregivers with information, specialist networks, support and clinical research opportunities. It does not replace a treating doctor or provide medical treatment directly. 

For someone beginning or reassessing myositis treatment in India, having reliable information and knowing where to seek specialist help can make the journey a little less uncertain.

FAQs

1. Can myositis be treated completely?
Myositis is generally managed rather than considered permanently cured. Many patients can achieve good disease control or remission with appropriate treatment, although the course varies by subtype and individual.

2. Will every patient with myositis need steroids?
Corticosteroids are commonly used for active muscle inflammation, but treatment is individualised. The decision depends on the patient's disease and overall health. 

3. Is physiotherapy safe for someone with myositis?
Supervised, appropriately tailored exercise is generally considered an important part of myositis care. The intensity should be guided by disease activity and the patient's functional condition. 

4. What happens if the first treatment does not work?
Doctors may adjust the dose, add or change immunosuppressive treatment, or consider options such as IVIG or rituximab in appropriate cases. 

5. Should myositis medicines be stopped when symptoms improve?
No. Medicines should only be reduced or stopped under medical supervision. Stopping treatment abruptly can be unsafe and may allow the disease to become active again.